ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1658

Which Factors Influence the Diagnostic Delay in Patients with Axial Spondyloarthritis?

Imke Redeker1, Johanna Callhoff1, Falk Hoffmann2, Hildrun Haibel3, Joachim Sieper4, Angela Zink5 and Denis Poddubnyy4, 1Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany, 2Department of Health Services Research, Carl von Ossietzky University, Oldenburg, Germany, 3Charité Universitätmedizin Berlin, Berlin, Germany, 4Rheumatology, Charité Universitätsmeidzin Berlin, Berlin, Germany, 5Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: axial spondyloarthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, October 22, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The interval from symptom onset till diagnosis in axial spondyloarthritis (axSpA) was reported a decade ago to be between five and ten years. The objective of this study was to explore if the diagnostic delay has improved over the past years and to analyse factors associated with the delay.

Methods: A sample of persons with axSpA (ICD-10 M45) stratified by age and sex was drawn from claims data of a large nationwide statutory health insurance fund in Germany. Each person in the sample received in 2015 a questionnaire gathering information on demographic, disease-related and socioeconomic characteristics. Disease-related parameters comprised the date of first symptoms, the date of diagnosis, the HLA-B27 status as well as the presence of extra-articular manifestations (uveitis, psoriasis, chronic-inflammatory bowel disease). Multivariable linear regression analysis was used to analyse factors associated with the diagnostic delay.   

Results: A total of 1,677 persons with axSpA were included in the analysis. The mean age was 56 years and 46% were female. The mean (95% confidence interval [CI]) diagnostic delay in the whole group was 5.7 (5.4 – 6.0) years and the median was 2.3 years (Fig. 1). Overall, 407 persons were diagnosed between 1996 and 2005 and 484 persons between 2006 and 2015. The diagnostic delay was not substantially different in both periods:  For patients diagnosed between 1996 and 2005 the mean (95% CI) diagnostic delay was 6.3 (5.6 – 7.0) years and the median was 2.6 years. For patients diagnosed between 2006 and 2015 the mean (95% CI) diagnostic delay was 7.4 (6.6 – 8.1) years and the median was 2.7 years. Persons with a long diagnostic delay were more often female and had less often a positive HLA-B27 status compared to persons with a short diagnostic delay (Tab. 1). Multivariable linear regression revealed that female sex, negative HLA-B27 status, prevalence of psoriasis and younger age at symptom onset are factors associated with a longer diagnostic delay (Tab. 2).

Conclusion: The mean diagnostic delay of about 7 years represents currently one of the major challenges in field of SpA. Female sex, negative HLA-B27 status, presence of psoriasis and younger age at symptom onset had a negative impact on the diagnostic delay.

Table 1. Main demographic, disease-related, lifestyle and socioeconomic characteristics of patients with axSpA stratified by the delay to diagnosis.

 

Total

 

N=1677

Delay to diagnosis

 <2.3 years

N=814

Delay to diagnosis

≥2.3 years

N=863

P value

Sex, female

45.9

40.6

50.8

<0.0001

Age, years

55.9 ± 0.1

54.3 ± 0.3

57.3 ± 0.3

<0.0001

Age at symptom onset, years

30.6 ± 0.3

33.1 ± 0.4

28.3 ± 0.3

<0.0001

Age at diagnosis, years

36.3 ± 0.3

33.8 ± 0.4

38.6 ± 0.4

<0.0001

HLA-B27 (+)

86.3

89.2

83.8

0.0103

BASDAI*, 0-10

4.5 ± 0

4.3 ± 0.1

4.7 ± 0.1

0.0002

BASFI*, 0-10

4.1 ± 0.1

3.8 ± 0.1

4.4 ± 0.1

<0.0001

Swollen/tender joints, 0-44

7 ± 0.2

6.6 ± 0.3

7.4 ± 0.3

0.1065

WHO-5 *, 0-100

45 ± 0.5

46.8 ± 0.7

43.3 ± 0.7

0.0012

Inflammatory bowel disease, ever

9

9.6

8.5

0.4481

Uveitis, ever

27.8

26.4

29.1

0.2347

Psoriasis, ever

15.1

13.9

16.2

0.2000

Educational level

 

 

 

0.0057

low

29.1

31.9

26.6

middle

42.8

38.8

46.4

high

28.1

29.3

27

Smoking, current*

19

20

18.1

0.3454

Pharmacological treatment*

 

 

 

 

NSAIDs

58.9

56.7

60.9

0.0883

non-opioid analgesics

22.2

20.3

24

0.0692

opioids

15.4

14

16.8

0.1265

bDMARDs

17.5

15.7

19.1

0.0609

csDMARDs

11.5

12.7

10.4

0.1403

steroids

19.5

18.7

20.2

0.4357

No pharmacological treatment*

22.5

25.1

20

0.0148

*referring to the time of questionnaire, not the time of diagnosis.

Values are presented as mean ± standard error of the mean for continuous characteristics and as percentages otherwise. P-values were assessed using analyses of variance for continuous characteristics and Rao-Scott chi-square tests otherwise.

WHO-5, 5-item World Health Organization Well-Being Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index, NSAIDs, Nonsteroidal Anti-Inflammatory Drugs; csDMARDs, conventional synthetic Disease-Modifying Anti-Rheumatic Drugs; bDMARDs, biological Disease-Modifying Anti-Rheumatic Drugs.

 

 

Table 2. Factors associated with diagnostic delay: results from multivariable linear regression analysis.

 

Reference

Estimate (95% CI)

Sex, female

male

1.85 (1.06, 2.65)

Age at symptom onset

per 10 years

-1.91 ( -2.29 , -1.53 )

HLA-B27 status, positive

negative

-3.61 (-5.14 , -2.07)

Psoriasis, yes

no

1.4 (0.08 , 2.73)

CI, Confidence Interval

 

 

 

 

 

 

 

 

 

 


Disclosure: I. Redeker, None; J. Callhoff, None; F. Hoffmann, None; H. Haibel, None; J. Sieper, None; A. Zink, None; D. Poddubnyy, None.

To cite this abstract in AMA style:

Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, Poddubnyy D. Which Factors Influence the Diagnostic Delay in Patients with Axial Spondyloarthritis? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/which-factors-influence-the-diagnostic-delay-in-patients-with-axial-spondyloarthritis/. Accessed December 8, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/which-factors-influence-the-diagnostic-delay-in-patients-with-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.